Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis

Arthritis and Rheumatism

Volumn 56, Issue 6, 2007, Pages 1985-1993

  Sfikakis, P P ^a,b   Papamichael, C ^a   Stamatelopoulos, K S ^a   Tousoulis, D ^a   Fragiadaki, K G ^a   Katsichti, P ^a   Stefanadis, C ^a   Mavrikakis, M ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b LAIKO GENERAL HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; BOSENTAN; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOMPERIDONE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; FUROSEMIDE; INTERCELLULAR ADHESION MOLECULE 1; LEVOTHYROXINE; METHOTREXATE; NIFEDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; VASCULOTROPIN; ENDOTHELIN RECEPTOR; SULFONAMIDE; VASCULOTROPIN A;

ADULT; AGED; ARTERIAL PRESSURE; ARTERY BLOOD FLOW; ARTERY DILATATION; ARTICLE; BLOOD VESSEL INJURY; BRACHIAL ARTERY; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; MALE; MEASUREMENT; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL; SCLERODERMA; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SYSTEMIC SCLEROSIS; TREATMENT DURATION; ULCER; ULTRASOUND; VASCULAR ENDOTHELIUM; VEIN OCCLUSION; BLOOD; BLOOD FLOW; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ECHOGRAPHY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PHYSIOLOGY; VASODILATATION;

ADMINISTRATION, ORAL; ADULT; AGED; BRACHIAL ARTERY; DOSE-RESPONSE RELATIONSHIP, DRUG; E-SELECTIN; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERTENSION, PULMONARY; INTERCELLULAR ADHESION MOLECULE-1; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, ENDOTHELIN; REGIONAL BLOOD FLOW; SCLERODERMA, SYSTEMIC; SULFONAMIDES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASODILATION;

EID: 34447544360     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22634     Document Type: Article

References (51)

1. Denton CP, Black CM, Abraham DJ. Mechanisms and consequences of fibrosis in systemic sclerosis [review]. Nat Clin Pract Rheumatol 2006;2:134-44.
2. Charles C, Clements P, Furst DE. Systemic sclerosis: hypothesis-driven treatment strategies [review]. Lancet 2006;367:1683-91.
3. Leroy EC. Systemic sclerosis: a vascular perspective [review]. Rheum Dis Clin North Am 1996;22:675-94.
4. Kahaleh MB. Vascular involvement in systemic sclerosis (SSc) [review]. Clin Exp Rheumatol 2004;22 Suppl 33:S19-23.
5. Matucci-Cerinic M, Kahaleh MB, LeRoy CE. Pathogenesis: vascular involvement. In: Clements PJ, Furst DE, editors. Systemic sclerosis. Baltimore: Williams & Wilkins; 1996. p. 153-74.
6. Mayes MD. Endothelin and endothelin receptor antagonists in systemic rheumatic diseases [review]. Arthritis Rheum 2003;48: 1190-9.
7. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-5.
8. Kim NH, Rubin LJ. Endothelin in health and disease: endothelin receptor antagonists in the management of pulmonary artery hypertension [review]. J Cardiovasc Pharmacol Ther 2002;7:9-19.
9. Clarke JG, Benjamin N, Larkin SW, Webb DJ, Davies GJ, Maseri A. Endothelin is a potent long-lasting vasoconstrictor in men. Am J Physiol 1995;257:H2033-5.
10. Roux S, Breu V, Ertel SI, Clozel M. Endothelin antagonism with bosentan: a review of potential applications [review]. J Mol Med 1999;77:364-76.
11. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study. Lancet 2001;358:1119-23.
12. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension [published erratum appears in N Engl J Med 2002;346:1258]. N Engl J Med 2002;346:896-903.
13. Denton CP, Humbert M, Rubin L, Black CM. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal trials and their open-label extensions. Ann Rheum Dis 2006;65:1336-40.
14. Girgis RE, Mathai SC, Krishnan JA, Wigley FM, Hassoun PM. Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases. J Heart Lung Transplant 2005;24:1626-31.
15. Joglekar A, Tsai FS, McCloskey DA, Wilson JE, Seibold JR, Riley DJ. Bosentan in pulmonary arterial hypertension secondary to scleroderma. J Rheumatol 2006;33:61-8.
16. Korn JH, Mayes M, Matucci Cerinic M, Ranisio M, Pope J, Hachulla E, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004;50:3985-93.
17. Schiffrin EL. Role of endothelin-1 in hypertension and vascular disease [review]. Am J Hypertens 2001;14:83-89S.
18. Stewart DJ, Levy RD, Cernacek P, Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med 1991;114:464-9.
19. Cines DB, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA, McEver RP, et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders [review]. Blood 1998;91: 3527-61.
20. Barton M, d'Uscio LV, Shaw S, Meyer P, Moreau P, Luscher TF. ETA receptor blockade prevents increased tissue endothelin-1, vascular hypertrophy, and endothelial dysfunction in salt-sensitive hypertension. Hypertension 1998;31:499-504.
21. Spiers JP, Kelso EJ, Siah WF, Edge G, Song G, McDermott BJ, et al. Alterations in vascular matrix metalloproteinase due to ageing and chronic hypertension: effects of endothelin receptor blockade. J Hypertens 2005;23:1717-24.
22. A receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A 1998;95: 14367-72.
23. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
24. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force [published erratum appears in J Am Coll Cardiol 2002;39:1082]. J Am Coll Cardiol 2002;39:257-65.
25. Tousoulis D, Antoniades C, Stefanadis C. Evaluating endothelial function in humans: a guide to invasive and non-invasive techniques [review]. Heart 2005;91:553-8.
26. Moyssakis I, Gialafos E, Vassiliou V, Taktikou E, Katsiari C, Papadopoulos D, et al. Aortic stiffness in systemic sclerosis is increased independently of the extent of skin involvement. Rheumatology (Oxford) 2005;44:251-4.
27. Holling HE, Boland HC, Russ E. Investigation of arterial obstruction using a mercury-in-rubber strain gauge. Am Heart J 1961;62: 194-205.
28. Zelis R, Mason DT, Braunwald E, Levy RI. Effects of hyperlipoproteinemias and their treatment on the peripheral circulation. J Clin Invest 1970;19:1007-15.
29. O'Rourke MF, Pauca A, Jiang XJ. Pulse wave analysis [review]. Br J Clin Pharmacol 2001;51:507-22.
30. Wilkinson IB, Fuchs SA, Jansen IM, Spratt JC, Murray GD, Cockcroft JR, et al. Reproducibility of pulse wave velocity and augmentation index measured by pulse wave analysis. J Hypertens 1998;16:2079-84.
31. Schacha L, Wigley FM. Targeting mediators of vascular injury in scleroderma [review]. Curr Opin Rheumatol 2002;14:686-93.
32. Joannides R, Haefeli WE, Linder L, Richard V, Bakkali EH, Thuillez C, et al. Nitric oxide is responsible for flow-mediated dilatation of human peripheral conduit arteries in vivo. Circulation 1995;91:1314-9.
33. Lekakis J, Mavrikakis M, Papamichael C, Papazoglou S, Economou O, Scotiniotis I, et al. Short-term estrogen administration improves abnormal endothelial function in women with systemic sclerosis and Raynaud's phenomenon. Am Heart J 1998;136: 905-12.
34. Mavrikakis ME, Lekakis JP, Papamichael CM, Stamatelopoulos KS, Kostopoulos CC, Stamatelopoulos SF. Ascorbic acid does not improve endothelium-dependent flow-mediated dilatation of the brachial artery in patients with Raynaud's phenomenon secondary to systemic sclerosis. Int J Vitam Nutr Res 2003;73:3-7.
35. Freedman RR, Girgis R, Mayes MD. Abnormal responses to endothelial agonists in Raynaud's phenomenon and scleroderma. J Rheumatol 2001;28:119-21.
36. Ikeda U, Yamamoto K, Maeda Y, Shimpo M, Kanbe T, Shimada K. Endothelin-1 inhibits nitric oxide synthesis in vascular smooth muscle cells. Hypertension 1997;29:65-9.
37. Allanore Y, Borderie D, Hilliquin P, Hernvann A, Levacher M, Lemarechal H, et al. Low levels of nitric oxide (NO) in systemic sclerosis: inducible NO synthase production is decreased in cultured peripheral blood monocyte/macrophage cells. Rheumatology (Oxford) 2001;40:1089-96.
38. Gonon AT, Erbas D, Broijersen A, Valen G, Pernow J. Nitric oxide mediates protective effect of endothelin receptor antagonism during myocardial ischemia and reperfusion. Am J Physiol Heart Circ Physiol 2004;286:H1767-74.
39. Girgis RE, Champion HC, Diette GB, Johns RA, Permutt S, Sylvester JT. Decreased exhaled nitric oxide in pulmonary arterial hypertension: response to bosentan therapy. Am J Respir Crit Care Med 2005;172:352-7.
40. Krum H, Viscoper RJ, Lacourciere Y, Budde M, Charlon V. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. N Engl J Med 1998;338:784-90.
41. Sfikakis PP, Tesar J, Baraf H, Lipnick R, Klipple G, Tsokos GC. Circulating intercellular adhesion molecule-1 in patients with systemic sclerosis. Clin Immunol Immunopathol 1993;68:88-92.
42. Vita JA, Keaney JF Jr, Larson MG, Keyes MJ, Massaro JM, Lipinska I, et al. Brachial artery vasodilator function and systemic inflammation in the Framingham Offspring Study. Circulation 2004;110:3604-9.
43. Witte DR, Broekmans WM, Kardinaal AF, Klopping-Ketelaars IA, van Poppel G, Bots ML, et al. Soluble intercellular adhesion molecule 1 and flow-mediated dilatation are related to the estimated risk of coronary heart disease independently from each other. Atherosclerosis 2003;170:147-53.
44. Xu SW, Denton CP, Dashwood MR, Abraham DJ, Black CM. Endothelin-1 regulation of intercellular adhesion molecule-1 expression in normal and sclerodermal fibroblasts. J Cardiovasc Pharmacol 1998;31 Suppl 1:S545-7.
45. Sfikakis PP, Mavrikakis M. Adhesion and lymphocyte co-stimulatory molecules in systemic rheumatic diseases [review]. Clin Rheumatol 1999;18:317-27.
46. Kuryliszyn-Moskal A, Klimiuk PA, Sierakowski S. Soluble adhesion molecules (sVCAM-1, sE-selectin), vascular endothelial growth factor (VEGF) and endothelin-1 in patients with systemic sclerosis: relationship to organ systemic involvement. Clin Rheumatol 2005;24:111-6.
47. Rondelet B, Kerbaul F, Motte S, van Beneden R, Remmelink M, Brimioulle S, et al. Bosentan for the prevention of overcirculation-induced experimental pulmonary arterial hypertension. Circulation 2003;107:1329-35.
48. Apras S, Ertenli I, Ozbalkan Z, Kiraz S, Ozturk MA, Haznedaroglu IC, et al. Effects of oral cyclophosphamide and prednisolone therapy on endothelial functions and clinical findings in patients with early diffuse systemic sclerosis. Arthritis Rheum 2003;48: 2256-61.
49. Williams MH, Das C, Handler CE, Akram MR, Davar J, Denton CP, et al. Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart 2006;92:926-32.
50. Abraham DJ, Vancheeswaran R, Dashwood MR, Rajkumar VS, Pantelides P, Xu SW, et al. Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am J Pathol 1997; 151:831-41.
51. Shi-Wen X, Chen Y, Denton CP, Eastwood M, Renzoni EA, Bou-Gharios G, et al. Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol Biol Cell 2004; 15:2707-19.